Alcon Inc. (ALC) Cash Flow Statement

The gap between net income and operating cash flow is substantial, particularly in quarters like 2025Q4 where OCF/NI hit 3.03, suggesting that non-cash charges such as depreciation and amortization are significant, but also that working capital swings are distorting earnings. The 2026Q2 net income of zero, per the income statement, contrasts sharply with $510 million in operating cash flow, implying that reported earnings understate the underlying cash-generating ability of the business. This divergence may indicate that the company's profitability is being temporarily suppressed by one-time items or strategic spending, but cash flow remains resilient, warranting a focus on operational cash generation rather than net income alone.

The FCF margin in 2026Q2 of 14.7% is in line with the trailing average, but the range from 8.1% in 2024Q1 to 25.0% in 2024Q3 indicates significant quarterly volatility, likely driven by working capital timing and capex phasing. Compared to peers like Hologic at 24.2% and IDEXX at 27.5%, Alcon's FCF margin appears moderate, but the consistency of positive FCF across all quarters suggests a durable cash flow profile. The recent dip in FCF margin from 20.6% in 2025Q3 to 14.7% in 2026Q2 may reflect increased capex and working capital outflows, but the absolute FCF of $414 million remains robust, supporting ongoing capital returns.

The capex-to-revenue ratio of 3.4% in 2026Q2 is the lowest in the series, down from a peak of 9.1% in 2024Q4, suggesting that the company is not in a heavy investment phase, possibly due to the completion of prior manufacturing expansions. This moderate capital intensity, relative to peers like STERIS at 15.3% FCF margin, implies that Alcon's asset base is not overly burdensome, but the low capex may also signal underinvestment if the company needs to upgrade its surgical equipment or contact lens production lines. The depreciation and amortization of $288 million in 2026Q2 exceeds capex of $96 million, indicating that the company is generating cash beyond its maintenance needs, which could support higher returns to shareholders or strategic acquisitions.

The negative working capital changes in 2026Q2 of -$225 million and 2026Q1 of -$269.7 million suggest that the company is using cash to fund receivables or inventory build-up, possibly ahead of new product launches or seasonal demand. Conversely, positive changes in 2025Q4 and 2025Q3 of $81 million and $78.9 million respectively indicate that the company was able to release cash from working capital, likely through improved collections or inventory management. These swings are not unusual for a medical device company with complex supply chains, but they do create noise in quarterly cash flow, and investors should monitor whether the recent outflows are a temporary phenomenon or a sign of structural inefficiency.

The combination of $174 million in dividends and $289 million in buybacks in 2026Q2 represents a payout ratio that exceeds net income, which was zero, suggesting that the company is funding shareholder returns through operating cash flow rather than earnings. This is a notable shift from earlier quarters where buybacks were more modest, such as $33 million in 2025Q1, and it may indicate management's confidence in the sustainability of cash generation despite the earnings dip. However, the $568 million acquisition outflow in 2025Q1, likely related to the Aerie Pharmaceuticals deal, shows that capital deployment is also directed toward strategic growth, and the balance between returning cash and investing in the business will be key to watch.